Consistent with our anti-metastatic effect of EZH2 inhibitor, recent studies19,39 that tested the effect of EZH2 HMT inhibitor (GSK-126) against TNBC and luminal B breast cancer, respectively, also witnessed the robust anti-metastatic potential of EZH2 inhibitor. The gene discussed is EZH2; the disease is breast cancer.